Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Company news centers on its off-the-shelf cell-therapy pipeline, including prulacabtagene leucel, or prula-cel, a CD20-targeted CAR gamma delta T cell therapy, and ADI-212, a PSMA-targeted candidate.
Recurring updates also cover clinical and regulatory disclosures, operating and financial results, biotechnology conference participation, inducement equity grants under Nasdaq rules, shareholder voting matters, Nasdaq listing compliance, and capital-structure actions involving common stock.
Adicet Bio (ACET) announced a public offering of 9,230,770 shares at $13.00 per share, aiming to raise gross proceeds of approximately $120 million. The offering includes a 30-day option for underwriters to buy an additional 1,344,743 shares. The expected closing date is February 12, 2021. Concurrently, Adicet plans a $15 million private placement with existing investors at the same price per share. Guggenheim Securities is the book-running manager for the offering.
Adicet Bio, Inc. (Nasdaq: ACET) announced an underwritten public offering of its common stock, aiming to raise funds for its allogeneic gamma delta T cell therapies for cancer. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. Adicet will enter into a stock purchase agreement with existing investors for $15 million in common stock at the public offering price, with initial and subsequent closings planned. The offering's completion is contingent on market conditions and other factors.
Adicet Bio, Inc. (Nasdaq: ACET) announced participation in two upcoming virtual investor conferences in January 2021. The first, the H.C. Wainwright Bioconnect 2021 Conference, will offer an on-demand presentation beginning January 11, 2021, at 6:00 AM ET. The second event, the B. Riley Securities' Oncology Investor Conference, features a fireside chat on January 20, 2021, at 3:30 PM ET. Both presentations will be accessible via the company’s website. Adicet Bio specializes in developing allogeneic gamma delta T cell therapies for cancer and other diseases.
Adicet Bio (Nasdaq: ACET), a biotechnology firm specializing in allogeneic gamma delta T cell therapies, announced participation in a fireside chat at The JMP Securities Hematology Summit on December 15, 2020, at 2:00 PM ET. The discussion will be led by Chen Schor, CEO, and Stewart Abbot, Ph.D., COO. Investors can access a live audio webcast on the company’s website, followed by a 30-day archive. Adicet's innovative therapies aim to enhance tumor targeting and improve immune responses for cancer treatment.
Adicet Bio, Inc. (Nasdaq: ACET) has appointed Bastiano Sanna, Ph.D., to its Board of Directors. Dr. Sanna, currently at Vertex Pharmaceuticals, is recognized for his extensive experience in cell therapy. His previous roles include CEO of Semma Therapeutics and Global Program Head at Novartis. The addition of Dr. Sanna is expected to strengthen Adicet’s pipeline, particularly in advancing ADI-001, their allogeneic gamma delta T cell therapy. Adicet focuses on innovative cancer treatments through enhanced immune response and tumor targeting.
Adicet Bio (Nasdaq: ACET), a biotechnology firm, announced its participation in several virtual investor conferences in November and December 2020. These events include:
- H.C. Wainwright Conference on November 12, 2020, at 9:00 AM ET
- B. Riley Securities Panel on November 12, 2020, at 2:00 PM ET
- Stifel Healthcare Conference on November 17, 2020, at 3:20 PM ET
- Evercore ISI HealthCONx Conference on December 1, 2020, at 1:00 PM ET
Live audio webcasts will be available on the company's website, with archived replays for 30 days post-event.
Adicet Bio, Inc. (Nasdaq: ACET) reported its third quarter 2020 financial results on November 5, 2020. Key milestones include the merger completion with resTORbio and FDA clearance for its IND application for ADI-001, a CAR gamma-delta T cell therapy for non-Hodgkin's lymphoma. R&D expenses rose to $8.9 million, while G&A expenses increased significantly to $7.7 million due to merger-related costs, leading to a net loss of $14.8 million. The company ended the quarter with $108.1 million in cash, indicating strong liquidity for future development.
Adicet Bio (Nasdaq: ACET) announced the appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr. Healey will oversee the development of genetically-modified T cell therapies, enhancing Adicet’s approach to cancer treatment. His extensive experience in cell therapy manufacturing, including roles at KBI Biopharma and Opexa Therapeutics, positions him as a key asset for the company. This leadership addition aims to strengthen the production and clinical development of Adicet's pipeline, especially the ADI-001 therapy, which is designed for improved tumor targeting and immune response.
Adicet Bio (Nasdaq: ACET) has received FDA clearance for its Investigational New Drug (IND) application for ADI-001, an allogeneic gamma delta T cell therapy targeting CD20, aimed at treating patients with B-cell non-Hodgkin's lymphoma (NHL). This significant milestone allows the company to commence its first-in-human clinical trial to assess safety and efficacy in up to 80 patients across various U.S. cancer centers. Interim clinical data is anticipated in 2021, potentially advancing the company's innovative pipeline of CAR gamma delta T cell therapies.
Adicet Bio, a biotechnology firm specializing in gamma delta T cell therapies, announced that CEO Chen Schor and COO Stewart Abbot will participate in a fireside chat at the Jefferies Cell Therapy Summit on October 5, 2020, at 2:30 PM ET. Investors can access a live audio webcast via Adicet's website, with an archived replay available for 30 days post-event. Adicet is focused on developing innovative cancer therapies utilizing engineered gamma delta T cells for improved tumor targeting and patient outcomes.